American Diabetes Association Professional Practice C: 11
However, individual responses vary widely, and some patients report increased bowel urgency or loose stools when starting these medications
Stenberg, E., Ottosson, J., Cao, Y., Lagstam, I
Development of GLP-1GIPLani We previously showed that covalent attachment of the PPAR/ co-agonist Tesa to a pharmacokinetically optimized GLP-1R agonist enabled targeted delivery of Tesa into GLP-1R-expressing cells, leading to greater weight loss and further improvement of glucose control relative to treatment with pharmacokinetically-matched GLP-1R agonist backbone 26 (Extended Data Fig
Consumers should not assume that every product marketed in the BPC category has an identical formulation, manufacturing process, impurity profile, stability profile, or delivery behavior